Isabella Gashaw

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Randomized Controlled Trial

Top Venues

Journal of molecular medicine (Berlin, Germany)

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Mattia Amoroso, Salvador Augustin, Sven Moosmang, Isabella Gashaw
Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. Journal of molecular medicine (Berlin, Germany) 102 (7) (2024)
Mattia Amoroso, Salvador Augustin, Sven Moosmang, Isabella Gashaw
Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. Journal of molecular medicine (Berlin, Germany) 102 (7) (2024)
Mattia Amoroso, Salvador Augustin, Sven Moosmang, Isabella Gashaw
Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. Journal of molecular medicine (Berlin, Germany) 102 (7) (2024)
Mattia Amoroso, Salvador Augustin, Sven Moosmang, Isabella Gashaw
Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. Journal of molecular medicine (Berlin, Germany) 102 (7) (2024)
Mattia Amoroso, Salvador Augustin, Sven Moosmang, Isabella Gashaw
Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. Journal of molecular medicine (Berlin, Germany) (2024)
Jan Hilpert, Esther Groettrup-Wolfers, Hristiyan Kosturski, Laura Bennett, Catriona L K Barnes, Kerstin Gude, Isabella Gashaw, Stefanie Reif, Thomas Steger-Hartmann, Christian Scheerans, Alexander Solms, Antje Rottmann, Guangping Mao, Charles Chapron
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis. Drugs in R&D (2023)
Stefan Klein, Isabella Gashaw, Sybille Baumann, Xinying Chang, Thomas Hummel, Uwe Thuß, Christian Friedrich
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. British journal of clinical pharmacology 88 (10) (2022)